Raised to date of the $1,070,000 goal.
Investment Type: Regulation CF
Minimum Investment: $500

Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. We invite you to join us in our efforts to develop these important, next-generation treatments.

Offering at a Glance:
Product Images
The Team
Dr. Jim Woody
Venture Capitalist, Founder, and Physician
Over 25 years of pharmaceutical research and management expertise. Current Chairman o..
Mr. Jeff Huitt
Jeff has more than 20 years' experience driving the financial function at start-ups and public..
Dr. Michael Shepard
Chief Science Officer
First FDA-approved monoclonal antibody therapy targeting breast cancer and other solid tumors...
Sir Marc Feldmann
Director & Co-founder
Discovered (with Ravinder Maini) anti-TNF therapy as an effective treatment for rheumatoid art..
Dr. Patrick Gray
Dr. Gray has focused on drug discovery for critical diseases. He has a passion for translating..
Dr. Lawrence Steinman, MD, PhD. Chairman
Scientific Advisor
Dr. Steinman is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford..
Laura Donlin, PhD
Scientific Advisor
The Donlin lab at the Hospital for Special Surgery (HSS) and Cornell Med in New York City expl..
Miriam Merad, MD, PhD
Scientific Advisor
Dr. Merad is Mount Sinai Endowed professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai S..
Alexander Tarakhovsky, MD, PhD
Scientific Advisor
Dr. Plutarch Papamarkou Professor and Head of the Laboratory for the Immune Cell Epigenetics and Signaling at The Rockefeller Universit..
Fiona McCann, PhD
Director of Immunology
Dr. McCann has her PhD from the University of Kent, UK, in 2000. She has 20 years of experience in immunology translational research at..
About the Team:
Inspired by the Greek word enosis, or “union,” Enosi Life Sciences was born when world-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard joined forces to focus on second-generation therapeutics for cancer and autoimmune diseases based on their previous successes. Feldma . . . . .
Read More

Enosi is providing an opportunity for all investors to participate in an early-stage biopharmaceutical company. Usually, this domain is occupied by Venture Capital firms. While there is an accompanying risk associated with such an opportunity, the rewards for success are also significant. Enosi’s founders and management are experienced in creating product opportunities and are dedicated to Enosi’s success.

Feldmann, Shepard and other management of Enosi are addressing serious problems in the treatment of autoimmune disease and cancer. Enosi’s unique approach comes from combining the expertise of its two founders to merge discovery technologies used in either autoimmune disease and cancer to be employed in both conditions. This is the first time this has been done.  

The current therapies for autoimmune disease often render patients susceptible to serious infections, cardiovascular problems, cancer, and even new autoimmune diseases. Enosi believes that it has a solution to many of these issues in its novel EN-1001 antibody program that specifically inhibits the inflammatory switch, TNFR1. Enosi is working toward displacing 30-year-old drugs, with a $40B market, with the 21st century targeted therapeutic that it hopes will be better at defeating disease, and safer for patients. This is just what Dr. Shepard has done for breast cancer with the discovery of Herceptin.

The Company’s long-term goals are to do superior (and efficient) research and development, make therapeutics that significantly enhance health, and provide good returns to its shareholders.

Enosi plans to progress to Regulation A, Tier 2, financing, and then list on an exchange. The Company will entertain other strategic transactions. However, success is not guaranteed.

The Company will post developments on the Title3Funds and Enosi website as well as other public forums.

Enosi is not listed on any exchanges and therefore does not have a way to establish an independent valuation. Based on assumptions regarding the Team, products and time to a meaningful clinical endpoint, we have estimated the Net Present Value of the Company at $29,270,673.

We cannot confirm that dividends will be paid out to investors. 

A summary of Enosi’s financial statement is included in the offering memorandum.

Term Sheets
Investor Perks
Financial Discussion
Market Landscape
Risks & Disclosures
Risks Related to the Company’s Business and Industry In order for the Company to compete and grow, it must attract, recruit, retain and develop the necessary personnel who have the needed experience. Recruiting and retaining highly qualified personnel is critical to our success. These demands may require us to hire additional personnel and will require our existing management personnel to develop addi . . . . .
Read More
Form C

Enosi Form C

Data Room

Early Investing Newsletter: Invest in the Brilliant Minds Behind Billions of Dollars in Pharma Sales

May 25, 2022
In a slightly less broken world, Enosi Life Sciences would not exist as is. Enosi is a tiny drug research and development company...

Enosi Life Sciences Appoints Dr. Patrick William Gray as Chief Executive Officer

Nov 22, 2021
EUGENE, Ore., Nov. 9, 2021 /PRNewswire/ -- Enosi Life Sciences, a drug research and development company focused on providing ..

Enosi on MoneyTV!

Sep 10, 2021
Mike Shepard, CEO and Co-Founder of Enosi joins Donald Baillargeon on MoneyTV to answer questions about Enosi Life Sciences crowdfundin..